0001104659-19-031227.txt : 20190522
0001104659-19-031227.hdr.sgml : 20190522
20190522213958
ACCESSION NUMBER: 0001104659-19-031227
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190522
FILED AS OF DATE: 20190522
DATE AS OF CHANGE: 20190522
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vertex Global Healthcare Fund I Pte Ltd.
CENTRAL INDEX KEY: 0001663140
STATE OF INCORPORATION: U0
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38916
FILM NUMBER: 19847799
BUSINESS ADDRESS:
STREET 1: 250 NORTH BRIDGE ROAD
STREET 2: #05-01 RAFFLES CITY TOWER
CITY: SINGAPORE
STATE: U0
ZIP: 179101
BUSINESS PHONE: 6568288088
MAIL ADDRESS:
STREET 1: 250 NORTH BRIDGE ROAD
STREET 2: #05-01 RAFFLES CITY TOWER
CITY: SINGAPORE
STATE: U0
ZIP: 179101
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS Ltd
CENTRAL INDEX KEY: 0001761612
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
BUSINESS ADDRESS:
STREET 1: B900 BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
BUSINESS PHONE: 011441223261503
MAIL ADDRESS:
STREET 1: B900 BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
3
1
a3.xml
3
X0206
3
2019-05-22
0
0001761612
BICYCLE THERAPEUTICS Ltd
BCYC
0001663140
Vertex Global Healthcare Fund I Pte Ltd.
C/O BICYCLE THERAPEUTICS PLC
B900, BABRAHAM RESEARCH CAMPUS
CAMBRIDGE
X0
CB22 3AT
UNITED KINGDOM
0
0
1
0
Series B1 Preferred Shares
Ordinary Shares
1272733
D
Series B1 Preferred Shares Warrants
2025-03-31
Series B1 Preferred Shares
141668
D
Series B2 Preferred Shares
Ordinary Shares
206767
D
Each Series B1 Preferred Share shall automatically convert into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
Share numbers give effect to the bonus shares issued to each holder of ordinary shares on the basis of 1.429 bonus shares for each ordinary share in issue, effective on May 13, 2019, which will be effective for the ordinary shares upon their conversion to ordinary shares upon the closing of the Issuer's initial public offering. The number of shares reflects the conversion of the Series B1 Preferred Shares and the Series B2 Preferred Shares to Ordinary Shares set out in footnotes (1) and (4).
The Warrants to purchase Series B1 Preferred Shares have an exercise price of a nominal value per share. The Warrants are immediately exercisable and expire on March 31, 2025.
Each Series B2 Preferred Share shall automatically convert into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
Name: /s/ Chua Kee Lock Title: Director
2019-05-22